Rafael Santana-Davila1, Aniko Szabo, Carlos Arce-Lara, Christina D Williams, Michael J Kelley, Jeff Whittle. 1. *Division of Hematology and Oncology, Clement J. Zablocki VA Medical Center; †Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI; ‡Durham VA Medical Center, Durham, NC; and §Division of Primary Care, Clement J. Zablocki VA Medical Center, Milwaukee, WI.
Abstract
BACKGROUND: While platinum-based doublet chemotherapy is standard of care for patients presenting with metastatic non-small-cell lung cancer, the optimal platinum agent (cisplatin versus carboplatin) is unclear. We therefore compared survival and toxicity among persons receiving these agents at Department of Veterans Affairs hospitals. METHODS: We used the Veterans Affairs Central Cancer Registry to identify veterans presented between 2001 and 2008 with metastatic non-small-cell lung cancer, then selected those receiving initial platinum doublet chemotherapy. We compared survival between those receiving cisplatin and carboplatin using multivariable Cox proportional hazards models and propensity score analyses to adjust for imbalances in demographics and clinical characteristics. RESULTS: We identified 4352 eligible persons; 4061 (93%) received carboplatin. Patients treated with cisplatin were younger (median age 61 versus 63, p < 0.01) and had less comorbidities (summary comorbidity score > 2, 7.7% versus 12.8%, p = 0.01) and higher eGFR (87 versus 84 mL/min/1.73 m). Median survival was similar for persons receiving cisplatin and carboplatin (8.1 versus 7.5 months, p = 0.54). In an adjusted survival analyses, the use of cisplatin was not associated with a better survival (hazard ratio 0.98, 95% confidence interval 0.84-1.14, p = 0.79). We performed subgroup analysis defined by histology and second agent, the hazard ratio for mortality ranged spanned 1 and none of these approached statistical significance (all p values > 0.20). Cisplatin-treated patients were more likely to have more hospitalization (1.7 versus 1.3, p < 0.01) and outpatient visits (11 versus 9.6, p < 0.01). Cisplatin-treated patient had more subsequent encounters for infection (41.6% versus 34.3%, p < 0.01) and acute kidney injury/dehydration (29.2% versus 15.5%, p < 0.01) CONCLUSIONS: : Patients receiving cisplatin and carboplatin-based doublets did not have significantly different survival, but cisplatin use was associated with an increase morbidity and healthcare use.
BACKGROUND: While platinum-based doublet chemotherapy is standard of care for patients presenting with metastatic non-small-cell lung cancer, the optimal platinum agent (cisplatin versus carboplatin) is unclear. We therefore compared survival and toxicity among persons receiving these agents at Department of Veterans Affairs hospitals. METHODS: We used the Veterans Affairs Central Cancer Registry to identify veterans presented between 2001 and 2008 with metastatic non-small-cell lung cancer, then selected those receiving initial platinum doublet chemotherapy. We compared survival between those receiving cisplatin and carboplatin using multivariable Cox proportional hazards models and propensity score analyses to adjust for imbalances in demographics and clinical characteristics. RESULTS: We identified 4352 eligible persons; 4061 (93%) received carboplatin. Patients treated with cisplatin were younger (median age 61 versus 63, p < 0.01) and had less comorbidities (summary comorbidity score > 2, 7.7% versus 12.8%, p = 0.01) and higher eGFR (87 versus 84 mL/min/1.73 m). Median survival was similar for persons receiving cisplatin and carboplatin (8.1 versus 7.5 months, p = 0.54). In an adjusted survival analyses, the use of cisplatin was not associated with a better survival (hazard ratio 0.98, 95% confidence interval 0.84-1.14, p = 0.79). We performed subgroup analysis defined by histology and second agent, the hazard ratio for mortality ranged spanned 1 and none of these approached statistical significance (all p values > 0.20). Cisplatin-treated patients were more likely to have more hospitalization (1.7 versus 1.3, p < 0.01) and outpatient visits (11 versus 9.6, p < 0.01). Cisplatin-treated patient had more subsequent encounters for infection (41.6% versus 34.3%, p < 0.01) and acute kidney injury/dehydration (29.2% versus 15.5%, p < 0.01) CONCLUSIONS: : Patients receiving cisplatin and carboplatin-based doublets did not have significantly different survival, but cisplatin use was associated with an increase morbidity and healthcare use.
Authors: Fabrice Barlesi; Arnaud Scherpereel; Achim Rittmeyer; Antonio Pazzola; Neus Ferrer Tur; Joo-Hang Kim; Myung-Ju Ahn; Joachim G J V Aerts; Vera Gorbunova; Anders Vikström; Elaine K Wong; Pablo Perez-Moreno; Lada Mitchell; Harry J M Groen Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: R Rosell; U Gatzemeier; D C Betticher; U Keppler; H N Macha; R Pirker; P Berthet; J L Breau; P Lianes; M Nicholson; A Ardizzoni; A Chemaissani; J Bogaerts; G Gallant Journal: Ann Oncol Date: 2002-10 Impact factor: 32.976
Authors: Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell Journal: J Natl Cancer Inst Date: 2007-06-06 Impact factor: 13.506
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Rafael Santana-Davila; Kiran Devisetty; Aniko Szabo; Rodney Sparapani; Carlos Arce-Lara; Elizabeth M Gore; Amy Moran; Christina D Williams; Michael J Kelley; Jeffrey Whittle Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: Steven D Criss; Meghan J Mooradian; Deirdre F Sheehan; Leyre Zubiri; Melissa A Lumish; Justin F Gainor; Kerry L Reynolds; Chung Yin Kong Journal: JAMA Oncol Date: 2019-03-01 Impact factor: 31.777
Authors: Stacyann Bailey; Qian Wang; Chung Yin Kong; Kimberly Stone; Rajwanth Veluswamy; Susan E Bates; Cardinale B Smith; Juan P Wisnivesky; Keith Sigel Journal: Curr Probl Cancer Date: 2022-05-21 Impact factor: 2.367
Authors: Eric S Kim; Andrea M Baran; Esther L Mondo; Thomas D Rodgers; Gradon C Nielsen; David W Dougherty; Kishan J Pandya; David Q Rich; Edwin van Wijngaarden Journal: PLoS One Date: 2017-12-11 Impact factor: 3.240